

CANCER EPIDEMIOLOGY,
BIOMARKERS & PREVENTION

TABLE OF CONTENTS

HIGHLIGHTS

2387 Selected Articles from This Issue

COMMENTARY

2389 **Translating Cancer Risk Prediction Models into Personalized Cancer Risk Assessment Tools: Stumbling Blocks and Strategies for Success**
Erika A. Waters, Jennifer M. Taber, Amy McQueen, Ashley J. Housten, Jamie L. Studts, and Laura D. Scherer

CEBP FOCUS

2396 **The National Cancer Institute Early Detection Research Network: Two Decades of Progress**
A C Robert C. Bast Jr and Sudhir Srivastava

2401 **The Early Detection Research Network: A National Infrastructure to Support the Discovery, Development, and Validation of Cancer Biomarkers**
A C Sudhir Srivastava and Paul D. Wagner

2411 **Biomarkers for Lung Cancer Screening and Detection**
A C Edwin J. Ostrin, David Sidransky, Avrum Spira, and Samir M. Hanash

2416 **Noninvasive Diagnostics for Early Detection of Lung Cancer: Challenges and Potential with a Focus on Changes in DNA Methylation**
A C Maria Farooq and James G. Herman

2423 **Lung Cancer and Immunity Markers**
A C Raymond J. Lim, Bin Liu, Kostyantyn Krysan, and Steven M. Dubinett

2431 **Biomarkers for Early Detection of Colorectal Cancer: The Early Detection Research Network, a Framework for Clinical Translation**
A C Robert S. Bresalier, William M. Grady, Sanford D. Markowitz, Hans Jørgen Nielsen, Surinder K. Batra, and Paul D. Lampe

2441 **Tumor DNA as a Cancer Biomarker through the Lens of Colorectal Neoplasia**
A C Joshua D. Cohen, Brenda Diergaarde, Nickolas Papadopoulos, Kenneth W. Kinzler, and Robert E. Schoen

2454 **Prostate Cancer Biomarker Development: National Cancer Institute's Early Detection Research Network Prostate Cancer Collaborative Group Review**
A C Michael A. Liss, Robin J. Leach, Martin G. Sanda, and Oliver J. Semmes

2463 **The Evolution of Our Understanding of the Biology of Cancer Is the Key to Avoiding Overdiagnosis and Overtreatment**
A C Kelly Hewitt, Jennifer Son, Alexa Glencer, Alexander D. Borowsky, Matthew R. Cooperberg, and Laura J. Esserman

2475 **Autoantibodies in Early Detection of Breast Cancer**
A C Femina Rauf, Karen S. Anderson, and Joshua LaBaer

2486 **Barrett's Esophagus and Esophageal Adenocarcinoma Biomarkers**
A C William M. Grady, Ming Yu, Sanford D. Markowitz, and Amitabh Chak

2495 **Biomarkers for the Early Detection of Hepatocellular Carcinoma**
A C Neehar D. Parikh, Anand S. Mehta, Amit G. Singal, Timothy Block, Jorge A. Marrero, and Anna S. Lok

2504 **Biomarkers and Strategies for Early Detection of Ovarian Cancer**
A C Robert C. Bast Jr, Zhen Lu, Chae Young Han, Karen H. Lu, Karen S. Anderson, Charles W. Drescher, and Steven J. Skates

2513 **Biomarkers and Strategy to Detect Preinvasive and Early Pancreatic Cancer: State of the Field and the Impact of the EDRN**
A C Ying Liu, Sukhwinder Kaur, Ying Huang, Johannes F. Fahrman, Jo Ann Rinaudo, Samir M. Hanash, Surinder K. Batra, Aatur D. Singhi, Randall E. Brand, Anirban Maitra, and Brian B. Haab

TABLE OF CONTENTS

- 2524** **Mesothelioma Biomarkers: A Review Highlighting Contributions from the Early Detection Research Network**
A C Harvey I. Pass, Marjan Alimi, Michele Carbone, Haining Yang, and Chandra M. Goparaju
- 2541** **The Potential of Circular RNAs as Cancer Biomarkers**
A C Jason R. Brown and Arul M. Chinnaiyan
- 2556** **Radiomics Improves Cancer Screening and Early Detection**
A C Robert J. Gillies and Matthew B. Schabath
- 2568** **Pitfalls in Cancer Biomarker Discovery and Validation with Emphasis on Circulating Tumor DNA**
A C Annie H. Ren, Clare A. Fiala, Eleftherios P. Diamandis, and Vathany Kulasingam
- 2575** **Adding Rigor to Biomarker Evaluations—EDRN Experience**
A C Ziding Feng and Margaret S. Pepe
- 2626** **Community-Acquired *Escherichia coli* Bacteremia after Age 50 and Subsequent Incidence of a Cancer Diagnosis: A Danish Population-Based Cohort Study**
Kirstine K. Søgaard, Katalin Veres, Christina M.J.E. Vandenbroucke-Grauls, Jan P. Vandenbroucke, Henrik T. Sørensen, and Henrik C. Schönheyder
- 2633** **Low Levels of Alcohol Consumption and Risk of Intestinal Metaplasia: A Cohort Study**
Kyungeun Kim, Yoosoo Chang, Jiin Ahn, Hyo-Joon Yang, and Seungho Ryu
- 2642** **Methylated DNA Markers of Esophageal Squamous Cancer and Dysplasia: An International Study**
A C Yi Qin, William Taylor, William R. Bamlet, Adharsh Ravindran, Alessia Buglioni, Xiaoming Cao, Patrick H. Foote, Seth W. Slettedahl, Douglas W. Mahoney, Paul S. Albert, Sungduk Kim, Nan Hu, Philip R. Taylor, Arash Etemadi, Masoud Sotoudeh, Reza Malekzadeh, Christian C. Abnet, Thomas C. Smyrk, David Katzka, Mark D. Topazian, Sanford M. Dawsey, David Ahlquist, John B. Kisiel, and Prasad G. Iyer
- 2651** **Extended HPV Genotyping to Compare HPV Type Distribution in Self- and Provider-Collected Samples for Cervical Cancer Screening**
Eliane Rohner, Claire Edelman, Busola Sanusi, John W. Schmitt, Anna Baker, Kirsty Chesko, Brian Faherty, Sean M. Gregory, LaHoma S. Romocki, Vijay Sivaraman, Julie A.E. Nelson, Siobhan O'Connor, Michael G. Hudgens, Andrea K. Knittel, Lisa Rahangdale, and Jennifer S. Smith
- 2662** **HPV Types in Cervical Precancer by HIV Status and Birth Region: A Population-Based Register Study**
Christina Carlander, Camilla Lagheden, Carina Eklund, Sara Nordqvist Kleppe, Mensur Dzabic, Philippe Wagner, Aylin Yilmaz, Kristina Elfgren, Anders Sönnnerborg, Pär Sparén, and Joakim Dillner
- 2669** **Association between Receipt of Guideline-Concordant Lung Cancer Treatment and Individual- and Area-Level Factors: A Spatio-Temporal Analysis**
Win Wah, Rob G. Stirling, Susannah Ahern, and Arul Earnest
- 2680** **A Large Cohort Study of Body Mass Index and Pancreatic Cancer by Smoking Status**
Eric J. Jacobs, Christina C. Newton, Victoria L. Stevens, Alpa V. Patel, W. Dana Flanders, and Susan M. Gapstur
- 2686** **Replication and Genetic Risk Score Analysis for Pancreatic Cancer in a Diverse Multiethnic Population**
David Bogumil, David V. Conti, Xin Sheng, Lucy Xia, Xiao-ou Shu, Stephen J. Pandol, William J. Blot, Wei Zheng, Loïc Le Marchand, Christopher A. Haiman, and Veronica Wendy Setiawan

RESEARCH ARTICLES

- 2583** **Examining COVID-19 Preventive Behaviors among Cancer Survivors in the United States: An Analysis of the COVID-19 Impact Survey**
A C Jessica Y. Islam, Marlene Camacho-Rivera, and Denise C. Vidot
- 2591** **Premature Years of Life Lost Due to Cancer in the United States in 2017**
A C Minkyong Song, Allan Hildesheim, and Meredith S. Shiels
- 2599** **Strategizing Screening for Melanoma in an Era of Novel Treatments: A Model-Based Approach**
Kemal Caglar Gogebakan, Elizabeth G. Berry, Alan C. Geller, Kemal Sonmez, Sancy A. Leachman, and Ruth Etzioni
- 2608** **Daily Physical Activity and Symptom Reporting in Breast Cancer Patients Undergoing Chemotherapy: An Intensive Longitudinal Examination**
Siobhan M. Phillips, Whitney A. Welch, Jason Fanning, Cesar A. Santa-Maria, Kara L. Gavin, Lisa A. Auster-Gussman, Payton Solk, Marilyn Lu, Erin Cullather, Seema A. Khan, Swati A. Kulkarni, William Gradishar, and Juned Siddique
- 2617** **Associations of Leisure-Time Physical Activity and Television Viewing with Life Expectancy Cancer-Free at Age 50: The ARIC Study**
Carmen C. Cuthbertson, Hazel B. Nichols, Xianming Tan, Anna Kucharska-Newton, Gerardo Heiss, Corinne E. Joshi, Elizabeth A. Platz, and Kelly R. Evenson

TABLE OF CONTENTS

2693 **Glucosamine and Chondroitin Supplements and Risk of Colorectal Adenoma and Serrated Polyp**

Dong Hoon Lee, Chao Cao, Xiaoyu Zong, Xuehong Zhang, Kelli O'Connell, Mingyang Song, Kana Wu, Mengmeng Du, Yin Cao, Edward L. Giovannucci, and Elizabeth D. Kantor

2702 **Evaluation of Circulating Tumor DNA for Methylated *BCAT1* and *IKZF1* to Detect Recurrence of Stage II/Stage III Colorectal Cancer (CRC)**

AC

Benjamin L. Musher, Joshua E. Melson, Gianni Amato, David Chan, Marisa Hill, Iftekhar Khan, Samith T. Kochuparambil, Susan E. Lyons, James Orsini Jr, Susanne K. Pedersen, Bruce Robb, Joel Saltzman, Jennifer Silinsky, Snigdha Gaur, Melissa K. Tuck, Lawrence C. LaPointe, and Graeme P. Young

2710 **Estimating Population-Based Recurrence Rates of Colorectal Cancer over Time in the United States**

Natalia Kunst, Fernando Alarid-Escudero, Eline Aas, Veerle M.H. Coupé, Deborah Schrag, and Karen M. Kuntz

2719 **Genetic Variants in the Regulatory T cell-Related Pathway and Colorectal Cancer Prognosis**

Sonja Neumeyer, Xinwei Hua, Petra Seibold, Lina Jansen, Axel Benner, Barbara Burwinkel, Niels Halama, Sonja I. Berndt, Amanda I. Phipps, Lori C. Sakoda, Robert E. Schoen, Martha L. Slattery, Andrew T. Chan, Manish Gala, Amit D. Joshi, Shuji Ogino, Mingyang Song, Esther Herpel, Hendrik Bläker, Matthias Kloor, Dominique Scherer, Alexis Ulrich, Cornelia M. Ulrich, Aung K. Win, Jane C. Figueiredo, John L. Hopper, Finlay Macrae, Roger L. Milne, Graham G. Giles, Daniel D. Buchanan, Ulrike Peters, Michael Hoffmeister, Hermann Brenner, Polly A. Newcomb, and Jenny Chang-Claude

2729 **Auto-antibodies to p53 and the Subsequent Development of Colorectal Cancer in a U.S. Prospective Cohort Consortium**

Julia Butt, William J. Blot, Kala Visvanathan, Loïc Le Marchand, Lynne R. Wilkens, Yu Chen, Howard D. Sesso, Lauren Teras, Marc D. Ryser, Terry Hyslop, Sylvia Wassertheil-Smoller, Lesley F. Tinker, John D. Potter, Mingyang Song, Sonja I. Berndt, Tim Waterboer, Michael Pawlita, and Meira Epplein

NULL RESULTS IN BRIEF

2735 **Mendelian Randomization Analysis of n-6 Polyunsaturated Fatty Acid Levels and Pancreatic Cancer Risk**

Dalia H. Ghoneim, Jingjing Zhu, Wei Zheng, Jirong Long, Harvey J. Murff, Fei Ye, Veronica Wendy Setiawan, Lynne R. Wilkens, Nikhil K. Khankari, Philip Haycock, Samuel O. Antwi, Yaohua Yang, Alan A. Arslan, Laura E. Beane Freeman, Paige M. Bracci, Federico Canzian, Mengmeng Du, Steven Gallinger, Graham G. Giles, Phyllis J. Goodman, Charles Kooperberg, Loïc Le Marchand, Rachel E. Neale, Ghislaine Scelo, Kala Visvanathan, Emily White, Demetrius Albanes, Pilar Amiano, Gabriella Andreotti, Ana Babic, William R. Bamlet, Sonja I. Berndt, Lauren K. Brais, Paul Brennan, Bas Bueno-de-Mesquita, Julie E. Buring, Peter T. Campbell, Kari G. Rabe, Stephen J. Chanock, Priya Duggal, Charles S. Fuchs, J. Michael Gaziano, Michael G. Goggins, Thilo Hackert, Manal M. Hassan, Kathy J. Helzlsouer, Elizabeth A. Holly, Robert N. Hoover, Verena Katske, Robert C. Kurtz, I-Min Lee, Núria Malats, Roger L. Milne, Neil Murphy, Ann L. Oberg, Miquel Porta, Nathaniel Rothman, Howard D. Sesso, Debra T. Silverman, Ian M. Thompson Jr, Jean Wactawski-Wende, Xiaoliang Wang, Nicolas Wentzensen, Herbert Yu, Anne Zeleniuch-Jacquotte, Kai Yu, Brian M. Wolpin, Eric J. Jacobs, Eric J. Duell, Harvey A. Risch, Gloria M. Petersen, Laufey T. Amundadottir, Peter Kraft, Alison P. Klein, Rachel Z. Stolzenberg-Solomon, Xiao-Ou Shu, and Lang Wu

ASPO REPORT

2740 **The Role of Dissemination and Implementation Research in Global Tobacco Control: A Report from the American Society of Preventive Oncology**

Ramzi G. Salloum, Mark Parascandola, Jennifer H. LeLaurin, and Donna Shelley


AC AC icon indicates AuthorChoice

For more information please visit www.aacrjournals.org

TABLE OF CONTENTS

ABOUT THE COVER

The cover image is adapted from Figure 3 in the article, “Prostate Cancer Biomarker Development: National Cancer Institute’s Early Detection Research Network Prostate Cancer Collaborative Group Review,” by Liss and colleagues. The figure shows an MRI-Ultrasound Fusion-guided technique for targeted prostate biopsy. Prostate cancer remains the most common non-skin cancer and second leading cause of death among men in the United States. Although progress has been made in diagnosis and risk assessment, many clinical questions remain regarding early identification of prostate cancer and management. The early detection of aggressive disease continues to provide high curative rates if diagnosed in a localized state. Unfortunately, prostate cancer displays significant heterogeneity within the prostate organ and between individual patients, making detection and treatment strategies complex. Although prostate cancer is common among men, the majority will not die from prostate cancer, introducing the issue of overtreatment as a major concern in clinical management of the disease. The focus of the future is to identify those at highest risk for aggressive prostate cancer and to develop prevention and screening strategies, as well as discerning the difference in malignant potential of diagnosed tumors. The Prostate Cancer Research Group of the National Cancer Institute’s Early Detection Research Network (EDRN) has contributed to the progress in addressing these concerns. The strong focus on biomarker application optimizes the development of biomarkers with clinical utility as well as the early adoption of disruptive technologies, such as MRI imaging, into biomarker development workflows. Likewise, efforts to validate findings from laboratories outside of the EDRN, such as polygenic risk scores and capture of in-depth data from clinical cohorts provide unique resources to the biomarker community. For more information, see the article beginning on page 2454.



Cancer Epidemiology, Biomarkers & Prevention

AACR American Association
for Cancer Research

29 (12)

Cancer Epidemiol Biomarkers Prev 2020;29:2387-2743.

Updated version Access the most recent version of this article at:
<http://cebp.aacrjournals.org/content/29/12>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://cebp.aacrjournals.org/content/29/12>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.